BioCentury
ARTICLE | Emerging Company Profile

GenKyoTex: Opportunity NOX

October 8, 2007 7:00 AM UTC

Nicotinamide-adenine dinucleotide phosphate oxidases are known to play a role in cardiovascular and neurological diseases, but blocking some isoforms is associated with toxicity, and determining selectivity for specific enzymes has so far not been possible. GenKyoTex S.A. believes it has the only available technology for isoform-selective screening of small molecules that inhibit NADPH oxidases, also called NOX enzymes.

"We're the first company to put 100% of our effort into developing NADPH oxidases," said co-founder Karl-Heinz Krause, who was among the first to discover the NOX family of free radical-generating enzymes...